p3 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion

Lung Cancer

Volumn 44, Issue 1, 2004, Pages 33-42

  Lee, Jin Hwa ^a   Hong, Young Sook ^b   Ryu, Jeong Seon ^c   Chang, Jung Hyun ^a  

^a Mokdong Hospital   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

^c Inha University Hospital   (South Korea)

Author keywords

FHIT; Loss of heterozygosity; Microsatellite instability; p3; Pleural effusion

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MICROSATELLITE DNA; PROTEIN P53; TUMOR MARKER; ACID ANHYDRIDE HYDROLASE; FRAGILE HISTIDINE TRIAD PROTEIN; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; FEMALE; FHIT GENE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC STABILITY; HETEROZYGOSITY; HUMAN; MALE; PLEURA CANCER; PLEURA EFFUSION; PLEURA FLUID; PLEURISY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RELIABILITY; EVALUATION; GENETICS; HETEROZYGOSITY LOSS; MIDDLE AGED; NUCLEOTIDE SEQUENCE; SENSITIVITY AND SPECIFICITY; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM PROTEINS; PLEURAL EFFUSION; SENSITIVITY AND SPECIFICITY;

EID: 1542268344     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.10.007     Document Type: Article

References (35)

1. Marel M., Stastny B., Melinova L., Svandova E., Light R.W. Diagnosis of pleural effusions. Experience with clinical studies, 1986-1990. Chest. 107:1995;1598-1603.
2. Fenton K.N., Richardson J.D. Diagnosis and management of malignant pleural effusions. Am. J. Surg. 170:1995;69-74.
3. Nance K.V., Shermer R.W., Askin F.B. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 4:1991;320-324.
4. Prakash U.B., Reiman H.M. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin. Proc. 60:1985;158-164.
5. Winkelmann M., Pfitzer P. Blind pleural biopsy in combination with cytology of pleural effusions. Acta Cytol. 25:1981;373-376.
6. Garcia-Pachon E., Padilla-Navas I., Dosda M.D., Miralles-Llopis A. Elevated level in CEA in nonmalignant pleural effusions. Chest. 111:1997;643-647.
7. Baxevanis C.N., Dedoussis G.V., Gritzapis A.D., Stathopoulos G.P., Papamichail M. Interleukin 1β synergises with interleukin 2 in the outgrowth of autologous tumor-reactive CD8+ effectors. Br. J. Cancer. 70:1994;625-630.
8. Druck T., Hadaczek P., Fu T.B., Ohta M., Siprashvili Z., Baffa R.et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res. 57:1997;504-512.
9. Sidransky D., Hollstein M. Clinical implications of the p53 gene. Annu. Rev. Med. 47:1996;285-301.
10. Chiba I., Takahashi T., Nau M.M., D'Amico D., Curiel D.T., Mitsudomi T. et al. Mutations in the p53 gene are frequent in primary, resected non small cell lung cancer. Oncogene. 5:1990;1603-1610.
11. Suzuki H., Takahashi T., Kuroishi T., Suyama M., Ariyoshi Y., Takahashi T.et al. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 52:1992;734-736.
12. Bennett W.P., Hussain S.P., Vahakangas K.H., Khan M.A., Shields P.G., Harris C.C. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. J. Pathol. 187:1999;8-18.
13. Denissenko M.F., Pao A., Tang M., Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 274:1996;430-432.
14. Husgafvel-Pursiainen K., Boffetta P., Kannio A., Nyberg F., Pershagen G., Mukeria A.et al. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res. 60:2000;2906-2911.
15. Yanagisawa K., Kondo M., Osada H., Uchida K., Takagi K., Masuda A.et al. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Cancer Res. 56:1996;5579-5582.
16. Fong K.M., Zimmerman P.V., Smith P.J. Correlation of loss of heterozygosity at 11p with tumor progression and survival in non-small cell lung cancer. Genes Chromosomes Cancer. 10:1994;183-189.
17. Sato S., Nakamura Y., Tsuchiya E. Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res. 54:1994;5652-5655.
18. Fong K.M., Zimmerman P.V., Smith P.J. Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung caner. Cancer Res. 55:1995;220-223.
19. Shiseki M., Kohno T., Nishikawa R., Sameshima Y., Mizoguchi H., Yokota J. Frequent allelic losses on chromosome 2q, 18q and 22q in advanced non-small cell lung carcinoma. Cancer Res. 54:1994;5643-5648.
20. Whang-Peng J., Kao-Shan C.S., Lee E.C., Bunn P.A., Carney D.N., Gazdar A.F.et al. Specific chromosome defect associated with human small cell lung cancer: deletion 3p(14-23). Science. 215:1982;181-182.
21. Wistuba I.I., Behrens C., Virmani A.K., Mele G., Milchgrub S., Girard L.et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 60:2000;1949-1960.
22. Endo C., Sagawa M., Sato M., Chen Y., Sakurada A., Aikawa H.et al. Sequential loss of heterozygosity in the progression of squamous cell carcinoma of the lung. Br. J. Cancer. 78:1998;612-615.
23. Wistuba I.I., Lam S., Behrens C., Virmani A.K., Fong K.M., LeRiche J.et al. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 89:1997;1366-1373.
24. Merlo A., Gabrielson E., Askin F., Sidransky D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res. 54:1994;640-642.
25. Spanakis N.E., Gorgoulis V., Mariatos G., Zacharatos P., Kotsinas A., Garinis G.et al. Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small lung carcinomas. Anticancer Res. 19:1999;1893-1899.
26. Zienolddiny SD, Ryberg MO, Arab V, Skaug, Hauge A. Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br J Cancer 2001;84:226-31.
27. Shin T.R., Hong Y.S., Kim J.K., Chang J.H. Genetic alteration of tumor suppressor gene and microsatellite in nonsmall cell lung cancer. Tuberc Respir Dis. 49:2000;453-465.
28. Kim C.H., Yoo C.G., Han S.K., Shim Y.S., Kim Y.W. Genetic instability of microsatellite sequences in non-small cell lung cancers. Lung Cancer. 21:1998;21-25.
29. Merlo A., Mabry M., Garbrielson E., Vollmer R., Baylin S.B., Sidransky D. Frequent microsatellite instability in primary small cell lung cancer. Cancer Res. 54:1994;2098-2101.
30. Chen X.Q., Stroun M., Magnenat J.L., Nicod L.P., Kurt A.M., Lyautey J.et al. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat. Med. 2:1996;1033-1035.
31. Steiner G., Schoenberg M.P., Linn J.F., Mao L., Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat. Med. 3:1997;621-624.
32. Powell C.A., Klares S., O'Connor G., Brody J.S. Loss of heterozygosity in epithelial cells obtained by bronchial brushing: clinical utility in lung cancer. Clin. Cancer. Res. 5:1999;2025-2034.
33. Liloglou T., Maloney P., Xinarianos G., Hulbert M., Walshaw M.J., Gosney J.R.et al. Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. Cancer Res. 61:2001;1624-1628.
34. Arvanitis D.A., Papadakis E., Zafiropoulos A., Spandidos D.A. Fractional allele loss is a valuable marker for human lung cancer detection in sputum. Lung Cancer. 40:2003;55-66.
35. Niklinski J., Hirsch F.R. Molecular approaches to lung cancer evaluation. Lung Cancer. 38:2002;S9-17.